Get the Stockscreener App
31.64
0.16%
-0.05
After Hours:
31.64
Immunocore Holdings Plc Adr stock is traded at $31.64, with a volume of 142.81K.
It is down -0.16% in the last 24 hours and up +2.53% over the past month.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
See More
Previous Close:
$31.69
Open:
$31.71
24h Volume:
142.81K
Relative Volume:
0.33
Market Cap:
$1.60B
Revenue:
$400.79M
Net Income/Loss:
$-35.58M
P/E Ratio:
-44.66
EPS:
-0.7085
Net Cash Flow:
$-15.09M
1W Performance:
-0.66%
1M Performance:
+2.53%
6M Performance:
-8.00%
1Y Performance:
+15.85%
1-Day Range:
$31.14
$32.19
1-Week Range:
$30.82
$32.75
52-Week Range:
$26.37
$40.71
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Name
Immunocore Holdings Plc Adr
Sector
Industry
Phone
01235 5430281
Address
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
31.64 | 1.61B | 400.79M | -35.58M | -15.09M | -0.7085 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Jan-07-26 | Upgrade | UBS | Sell → Buy |
| Oct-31-25 | Initiated | Wells Fargo | Overweight |
| Sep-18-25 | Resumed | Guggenheim | Neutral |
| Aug-25-25 | Resumed | Jefferies | Buy |
| May-27-25 | Initiated | Deutsche Bank | Buy |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-24 | Downgrade | Mizuho | Outperform → Neutral |
| Oct-24-24 | Initiated | UBS | Sell |
| Oct-07-24 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-23 | Initiated | Robert W. Baird | Outperform |
| Sep-13-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-13-23 | Initiated | Needham | Buy |
| Aug-16-23 | Initiated | CapitalOne | Overweight |
| Jul-17-23 | Initiated | Canaccord Genuity | Hold |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-30-23 | Initiated | Guggenheim | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Dec-16-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-30-22 | Initiated | Barclays | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| Sep-08-22 | Initiated | Ladenburg Thalmann | Buy |
| Aug-08-22 | Initiated | Cowen | Outperform |
| Aug-02-22 | Initiated | BTIG Research | Buy |
| Feb-08-22 | Initiated | H.C. Wainwright | Buy |
| Oct-20-21 | Initiated | Oppenheimer | Outperform |
| Mar-02-21 | Initiated | Goldman | Neutral |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
| Mar-02-21 | Initiated | Jefferies | Buy |
View All
Immunocore Holdings Plc Adr Stock (IMCR) Latest News
Immunocore (IMCR) upgraded to strong buy: Here's why - MSN
Immunocore Holdings Plc (NASDAQ: IMCR) plans same‑day cashless sale of 25,000 ADRs - Stock Titan
Immunocore Holdings stock: What you need to know for smart investing now - AD HOC NEWS
Immunocore Holdings plc (IMCR) stock price, news, quote and history - uk.finance.yahoo.com
Immunocore Holdings stock: Precision Oncology Leader with ImmTAC Innovation - AD HOC NEWS
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Short Interest Down 15.4% in March - MarketBeat
Jefferies reiterates Hold on Immunocore stock amid competitor data By Investing.com - Investing.com South Africa
Immunocore (IMCR) upgraded to strong buy: Here's what you should know - MSN
Jefferies downgrades Immunocore stock rating on revenue concerns - Investing.com
Jefferies downgrades Immunocore stock rating on revenue concerns By Investing.com - Investing.com South Africa
Insider sells 11,832 ADRs at Immunocore (NASDAQ: IMCR) in cashless exercise - Stock Titan
Immunocore at Leerink Conference: Strategic Growth and Innovation - Investing.com
Q1 Earnings Forecast for Immunocore Issued By HC Wainwright - Defense World
What is HC Wainwright's Estimate for Immunocore Q1 Earnings? - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
T. Rowe Price (IMCR) lists 3,041,904 ADRs, a 6.0% stake in Immunocore - stocktitan.net
FY2027 EPS Estimates for Immunocore Cut by HC Wainwright - MarketBeat
Immunocore to present at upcoming investor conferences - GlobeNewswire Inc.
Immunocore (NASDAQ:IMCR) Price Target Raised to $75.00 at Needham & Company LLC - Defense World
Immunocore Q4 Earnings Call Highlights - Yahoo Finance
Immunocore Holdings earnings missed by $0.40, revenue fell short of estimates - Investing.com South Africa
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up - Finviz
JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations - Finviz
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y - Finviz
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y - Finviz
Earnings call transcript: Immunocore Holdings Q4 2025 reveals strong growth, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Immunocore Holdings Q4 2025 reveals strong growth, stock dips - Investing.com India
Immunocore earnings ahead as melanoma pipeline advances By Investing.com - Investing.com India
Immunocore earnings ahead as melanoma pipeline advances - Investing.com
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down - Finviz
Immunocore (NASDAQ:IMCR) CAO John Goll Sells 698 Shares - MarketBeat
Leger Tina Amber St Sells 1,000 Shares of Immunocore (NASDAQ:IMCR) Stock - MarketBeat
Immunocore (NASDAQ:IMCR) CEO Bahija Jallal Sells 11,474 Shares - MarketBeat
David Berman Sells 5,965 Shares of Immunocore (NASDAQ:IMCR) Stock - MarketBeat
[144] Immunocore Holdings plc SEC Filing - Stock Titan
Immunocore (IMCR) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Immunocore Q4 2025 Earnings Call Transcript - MarketBeat
SNY Stock Falls After Board Suddenly Makes Leadership Change - Finviz
Immunocore Holdings PLC Sponsored ADR $IMCR Stock Holdings Lifted by Candriam S.C.A. - MarketBeat
Immunocore Holdings PLC Sponsored ADR $IMCR Shares Sold by Principal Financial Group Inc. - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
GSK Gets EU Approval for Expanded Use of Nucala in COPD - Finviz
HC Wainwright Weighs in on Immunocore FY2030 Earnings - Defense World
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates - Finviz
HC Wainwright Predicts Immunocore FY2030 Earnings - MarketBeat
NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View - Finviz
Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU - The Globe and Mail
Immunocore Holdings Plc Adr Stock (IMCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):